(CercleFinance.com) – Fresenius Medical Care publishes adjusted EPS for 2023, up 4% to 2.58 euros, as well as adjusted operating income of 1.74 billion, up 15% at exchange rates constant, higher than the upper limit of its target range.
It highlights ‘successful execution of the recovery plan, which has resulted in significant improvements in workforce productivity in care delivery and positive pricing in care enablement’.
At nearly 19.5 billion euros, the turnover of the German dialysis specialist remained stable in published data, but increased by 5% excluding currency effects, driven by favorable developments in its activities.
A dividend of 1.19 euros per share will be proposed for the past year. For 2024, continued growth in turnover and an acceleration in the increase in operating profit are planned by management.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
